论文部分内容阅读
目的 :了解肌萎缩侧索硬化 (ALS)患者血浆和脑脊液谷氨酸浓度改变 ,以及药物干预对谷氨酸水平的影响。方法 :应用HPLC方法对ALS患者进行血浆和脑脊液谷氨酸测定。结果 :①患者血浆中存在兴奋性谷氨酸显著增高 ,谷氨酸浓度与性别、年龄、病程均无关。②力鲁唑 (力如太 )治疗 1个月后 ,血浆谷氨酸浓度下降 ,而环磷酰胺治疗变化不明显。③脑脊液中谷氨酸浓度未见明显变化。结论 :ALS患者存在谷氨酸代谢异常 ,但谷氨酸可能不是ALS致病的惟一途径。
OBJECTIVE: To investigate the changes of glutamate concentration in plasma and cerebrospinal fluid in patients with amyotrophic lateral sclerosis (ALS) and the effect of drug intervention on glutamate levels. Methods: Plasma and cerebrospinal fluid glutamate levels were measured by HPLC in patients with ALS. Results: ① There was a significant increase of excitatory glutamate in plasma of patients, and the concentration of glutamate was not related to gender, age and course of disease. ② riluzole (force as too) after 1 month of treatment, plasma glutamate concentration decreased, while cyclophosphamide treatment did not change significantly. ③ cerebrospinal fluid glutamate concentration no significant change. CONCLUSION: Glutamate metabolism is abnormal in patients with ALS, but glutamate may not be the only pathogen of ALS.